Fresenius SE & Co. KGaA

Earnings Release • Nov 3, 2016

Factsheet Q3/2016

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 230,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	Q1 – 3/ 2016	Q1–3 / 2015	Change	FY/2015
Sales and Earnings
Sales	21,345	20,369	5%	27,626
EBIT 1	3,092	2,849	9%	3,958
Net income 1,2	1,154	1,009	14%	1,423
Earnings per ord. share in €1,2	2.11	1.86	13%	2.61
Balance sheet and cash flow
Total assets	44,075		3%	42,959
Non-current assets	32,940		1%	32,480
Equity 3	19,086		6%	18,003
Equity ratio 3	43%		--	42%
Net debt/EBITDA 1,4,6	2.50		--	2.68
Investments 5	1,636	1,222	34%	2,029
Operating cash flow	2,259	2,151	5%	3,327
Operating cash flow in % of sales	10.6%	10.6%	--	12.0%
Profitability
EBIT margin1	14.5%	14.0%	--	14.3%
Return on equity after taxes (ROE) 1,2	13.4%	12.8%	--	13.0%
Return on operating assets (ROOA) 1,6	10.3%	9.9%	--	10.1%
Return on invested capital (ROIC) 1,6	8.6%	8.0%	--	8.3%
Employees	231,432		4%	222,305

¹ 2015 before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA 3

Including noncontrolling interest ⁴ At LTM average exchange rates for both net debt and EBITDA

5 Investments in property, plant and equipment, and intangible assets, acquisitions

6 Pro forma acquisitions

SALES BY REGION Latin America and Others 5% Asia-Pacific 10% Europe 38% North America 47% Q1 – 3/2016: €21.3 billion

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

31%1	100%		100%	77%
Fresenius Medical Care	Fresenius Kabi		Fresenius Helios	Fresenius Vamed

1 As of September 30, 2016

BUSINESS SEGMENTS

€ in millions		Q1 – 3/ 2016	Q1 – 3/ 2015	Change	FY/2015
	Sales EBIT	11,847 1,659	11,118 1,494	7% 11%	15,086 2,097
	Sales EBIT 1	4,457 916	4,431 872	1% 5%	5,950 1,189
	Sales EBIT 1	4,382 507	4,167 472	5% 7%	5,578 640
	Sales EBIT	740 31	731 30	1% 3%	1,118 64

2015 before special items

1

• ▶ Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of September 30, 2016, Fresenius Medical Care was treating 306,366 patients in 3,579 dialysis clinics.
• ▶ Fresenius Kabi Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
• ▶ Fresenius Helios is Germany's largest hospital operator. HELIOS operates 112 hospitals, thereof 88 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. HELIOS treats more than 4.7 million patients per year, thereof approximately 1.3 million inpatients, and operates approximately 35,000 beds.
• ▶ Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

SALES BY BUSINESS SEGMENT

Factsheet Q3/2016, © Fresenius SE & Co. KGaA Investor Relations Page 1/2

FRESENIUS SHARE / ADR

Securities code no. ISIN Ticker symbol ADR CUSIP	Share
	578 560
	DE0005785604
	FRE
	35804M105
ADR Ticker symbol	FSNUY
Number of shares (September 30, 2016)	546.932.731
Market capitalization (September 30, 2016)	€38.8 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX

DAX Fresenius share

DEVELOPMENT SHARE DIVIDENDS IN €

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Stephan Sturm (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Matu rity
Fresenius SE &Co. KGaA 1	XS1013954646	€300	2.375%	2019
Fresenius SE &Co. KGaA 1	XS0759200321	€500	4.25%	2019
Fresenius SE &Co. KGaA 1	XS0873432511	€500	2.875%	2020
Fresenius SE &Co. KGaA 1	XS1013955379	€450	3.00%	2021
Fresenius SE &Co. KGaA 1	XS1026109204	€450	4.00%	2024
Fresenius US Finance II, Inc.	USU31436AG04	US\$300	4.25%	2021
Fresenius US Finance II, Inc.	USU31436AH86	US\$300	4.50%	2023
Convertible bonds
Fresenius SE & Co. KGaA	DE000A1YC3T6	€500	0.00%	2019

Bonds of Fresenius Medical Care can be found under www.freseniusmedicalcare.com/en/home/

investors/credit-relations 1 Issuer substitution as of July 29, 2016, previously Fresenius Finance B.V.

SHARE PERFORMANCE ¹

1 month	+9%
9 month	+8%
1 year	+18%
5 years	+220%
10 years	+363%

1 Effective date/closing price: September 30, 2016

GROUP OUTLOOK 2016

	Targets 2016
Sales, growth (in constant currency)	6%– 8%
Net income 1 , growth (in constant currency)	12%– 14%
Capital expenditure	~6% of group sales

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA;

2015 before integration costs (€12 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the efficiency program at Fresenius Kabi (€105 million before tax) and before disposal gains from the divestment of two HELIOS hospitals (€34 million before tax)

For the outlook of the business segments please see our Investor News of October 27, 2016.

FINANCIAL CALENDAR

	Dates
Report on Fiscal Year 2016	February 22, 2017
Report on 1st quarter 2017	May 3, 2017
Annual General Meeting, Frankfurt/Main	May 12, 2017
Report on 2nd quarter 2017	August 1, 2017
Report on 3rd quarter 2017	November 2, 2017

Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H. e-mail: ir-fre@fresenius.com Internet:

Markus Georgi

Senior Vice President Telephone: ++49 61 72 6 08-24 85 Investor Relations Telefax: ++49 61 72 6 08-24 88

Follow us on twitter and linkedin